These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3929386)

  • 1. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions.
    Fareed J; Walenga JM; Kumar A; Rock A
    Semin Thromb Hemost; 1985 Apr; 11(2):155-75. PubMed ID: 3929386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions.
    Fareed J; Kumar A; Rock A; Walenga JM; Davis P
    Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the thrombogenic effects of recombinant tissue factor. In vivo versus ex vivo findings.
    Callas DD; Bacher P; Fareed J
    Semin Thromb Hemost; 1995; 21(2):166-76. PubMed ID: 7660139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
    Walenga JM; Petitou M; Lormeau JC; Samama M; Fareed J; Choay J
    Thromb Res; 1987 Apr; 46(2):187-98. PubMed ID: 3603420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.
    Fareed J; Walenga JM; Williamson K; Emanuele RM; Kumar A; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):56-74. PubMed ID: 3883500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant and antithrombotic actions of a semisynthetic beta-1,3-glucan sulfate.
    Alban S; Jeske W; Welzel D; Franz G; Fareed J
    Thromb Res; 1995 May; 78(3):201-10. PubMed ID: 7631300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of recombinant hirudin and standard heparin in the Wessler model.
    Bara L; Bloch MF; Samama MM
    Thromb Res; 1992 Oct; 68(2):167-74. PubMed ID: 1475779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental venous thrombosis induced by homologous serum in the rat.
    Millet J; Vaillot M; Theveniaux J; Brown NL
    Thromb Res; 1996 Feb; 81(4):497-502. PubMed ID: 8907300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
    Prowse CV; Williams AE
    Thromb Haemost; 1980 Oct; 44(2):81-6. PubMed ID: 6779401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AGA Clinical Practice Update: Coagulation in Cirrhosis.
    O'Leary JG; Greenberg CS; Patton HM; Caldwell SH
    Gastroenterology; 2019 Jul; 157(1):34-43.e1. PubMed ID: 30986390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model.
    Thomas DP; Merton RE; Gray E; Barrowcliffe TW
    Thromb Haemost; 1989 Apr; 61(2):204-7. PubMed ID: 2546282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The venous antithrombotic profile of naroparcil in the rabbit.
    Millet J; Theveniaux J; Brown NL
    Thromb Haemost; 1994 Dec; 72(6):874-9. PubMed ID: 7740457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
    Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Zang WJ; Wang B
    Thromb Res; 2011 Nov; 128(5):463-9. PubMed ID: 21924458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation.
    Cade JF; Buchanan MR; Boneu B; Ockelford P; Cater CJ; Cerskus AL; Hirsh J
    Thromb Res; 1984 Sep; 35(6):613-25. PubMed ID: 6506020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
    Fioravanti C; Burkholder D; Francis B; Siegl PK; Gibson RE
    Thromb Res; 1993 Aug; 71(4):317-24. PubMed ID: 8236160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
    Kaiser B; Fareed J
    Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications.
    Gitel SN; Wessler S
    J Lab Clin Med; 1979 Sep; 94(3):481-8. PubMed ID: 469382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit.
    Berry CN; Girard D; Girardot C; Lochot S; Lunven C; Visconte C
    Semin Thromb Hemost; 1996; 22(3):233-41. PubMed ID: 8836007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.